BioPharmSignal logoBioPharmSignal

Biotech News

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital

OraSure Technologies, Inc. (OSUR)OraSure Technologies, Inc.Commercial

Company Has Demonstrated Momentum on Transformation Strategy with Significant Regulatory and Commercial Milestones Approaching in 2026 Highlights Extensive Engagement with Altai Altai Has Rejected All Settlement Proposals and Is Singularly Focused on Securing Board Representation for Its Founder to

Related news

VRAXVirax Biolabs2026-07-16 11:30 EST

Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

BIAFbioAffinity Technologies, Inc.2026-07-07 12:46 EST

bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues

OSUROraSure Technologies, Inc.2026-04-22 20:10 EST

OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th

OSUROraSure Technologies, Inc.2026-04-17 00:10 EST

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

LUCDLucid Diagnostics2026-08-05 12:46 EST

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

LUCDLucid Diagnostics2026-08-04 12:30 EST

Lucid Diagnostics to Participate in Upcoming Investor Conferences

VRAXVirax Biolabs2026-07-09 11:30 EST

Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics

RHHBYRoche Holdings AG2026-07-23 05:00 EST

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc

BIAFbioAffinity Technologies, Inc.2026-05-12 13:15 EST

bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026

BDSXBiodesix2026-08-05 20:01 EST

Biodesix Announces Second Quarter 2026 Results and Highlights

View all latest news

OraSure Technologies, Inc.

Decentralized Diagnostics OraSure Technologies develops point-of-need and at-home diagnostic tests intended to make testing more accessible, private and convenient. Rapid-Test Portfolio The company's products cover infectious diseases and other conditions across consumer, clinical, public-health and community settings. Subsidiaries...

Recent company news

OSUROraSure Technologies, Inc.2026-08-05 20:05 EST

OraSure Announces Second Quarter 2026 Financial Results

OSUROraSure Technologies, Inc.2026-07-22 20:10 EST

OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th

OSUROraSure Technologies, Inc.2026-07-21 20:30 EST

OraSure Receives Emergency Use Authorization for Second Generation Ebola Test

OSUROraSure Technologies, Inc.2026-06-11 12:00 EST

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OSUROraSure Technologies, Inc.2026-05-06 20:05 EST

OraSure Announces First Quarter 2026 Financial Results

Stock data

Close
3.77 USD
Market cap
275.39M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States